

Prof. Gül BAŞARAN



Personal Information

Mobile Phone: [+90 532 667 5589](tel:+905326675589)

Office Phone: [+90 216 649 4444](tel:+902166494444) Extension: 4542

Fax Phone: [+90 216 649 5291](tel:+902166495291)

Email: gul.basaran@acibadem.edu.tr

Other Email: gul.basaran@acibadem.com

Web: <https://avesis.acibadem.edu.tr/gul.basaran>

Address: Altunizade Mah. Tophanelioğlu Cad. Okul Sok. No:1 Üsküdar 34662 İstanbul



International Researcher IDs

ScholarID: g

ORCID: 0000-0002-0775-6180

Publons / Web Of Science ResearcherID: AAT-7780-2020

Yoksis Researcher ID: 191635

Education Information

Post Doctorate of Medicine, Universite Libre de Bruxelles, Jules Bordet Enstitüsü, Tıbbi Onkoloji Bilim Dalı, Belgium 2001 - 2003

Post Doctorate of Medicine, Marmara University, School Of Medicine, Internal Medical Sciences, Turkey 1999 - 2003

Expertise In Medicine, Marmara University, School Of Medicine, Tıp Fakültesi, Turkey 1995 - 1999

Expertise In Medicine, Nöroloji, Turkey 1994 - 1995

Undergraduate, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Tıp Fakültesi, Turkey 1987 - 1993

Foreign Languages

English, C2 Mastery

Research Areas

Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Health Sciences

Academic Titles / Tasks

Professor, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2011 - Continues

Professor, Marmara University, School Of Medicine, Tıbbi Onkoloji Bilim Dalı, 2011 - 2011

Associate Professor, Marmara University, School Of Medicine, Tıbbi Onkoloji Bilim Dalı, 2005 - 2010

Expert PhD, Marmara University, School Of Medicine, Tıbbi Onkoloji Bilim Dalı, 2003 - 2005

Expert PhD, Universite Libre de Bruxelles, Jules Bordet Enstitüsü, Kemoterapi Ünitesi, 2001 - 2003

Expert PhD, Marmara University, School Of Medicine, Tibbi Onkoloji Bilim Dalı, 1999 - 2001

Specialization Student, Marmara University, School Of Medicine, Internal Medical Sciences, 1995 - 1999

Specialization Student, Nöroloji, Nöroloji Ana Bilim Dalı, 1994 - 1995

Academic and Administrative Experience

Head of Department, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2023 - Continues

Program Koordinatörü, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2012 - 2022

Courses

Breast Cancer: screening, diagnosis, risk factors, principles of therapy, Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014, 2012 - 2013, 2011 - 2012

Review of history taking and physical examination, Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014, 2012 - 2013, 2011 - 2012

Introduction to IM , Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014, 2012 - 2013, 2011 - 2012

Principles of Cancer Therapy, Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014, 2012 - 2013, 2011 - 2012

Jury Memberships

Appointment to Academic Staff - Associate Professorship, Appointment to Academic Staff - Associate Professorship, Acibadem Mehmet Ali Aydınlar University, January, 2024

Appointment to Academic Staff - Associate Professorship, Appointment to Academic Staff - Associate Professorship, Acibadem Mehmet Ali Aydınlar University, January, 2024

Appointment to Academic Staff - Associate Professorship, Appointment to Academic Staff - Associate Professorship, Acibadem Mehmet Ali Aydınlar University, December, 2023

Appointment to Academic Staff - Associate Professorship, Appointment to Academic Staff - Associate Professorship, Acibadem Mehmet Ali Aydınlar University, March, 2023

Appointment to Academic Staff - Associate Professorship, Appointment to Academic Staff - Associate Professorship, Acibadem Mehmet Ali Aydınlar University, March, 2023

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study**
ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., Uslu R., Mandel N. M., YALÇIN Ş., Teomete M., et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, no.5, pp.562-568, 2024 (SCI-Expanded)
- II. **Recommendations for cyclin-dependent kinase 4/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review)**
Teomete M., ÇABUK D., Korkmaz T., Seber S., Ozturk O. F., Aver B., Karaalp A., BAŞARAN G. ONCOLOGY LETTERS, no.4, 2024 (SCI-Expanded)
- III. **Frequency of germline pathogenic variants in breast cancer predisposition genes among young**

Turkish breast cancer patients

Isiklar A. D., Aliyeva L., Yesilyurt A., Soyder A., Başaran G.

Breast Cancer Research and Treatment, vol.202, no.2, pp.297-304, 2023 (SCI-Expanded)

- IV. **Evaluation of bone health in breast cancer patients with germline pathogenic variants**
Isiklar A., BAŞARAN G.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, no.5, pp.148-152, 2023 (SCI-Expanded)
- V. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.**
Kahraman S., Erul E., Seyyar M., Gumusay Ö., Bayram E., Demirel B. C., Acar O., Aksoy S., Baytemur N. K., Sahin E., et al.
Future oncology (London, England), 2023 (SCI-Expanded)
- VI. **Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.**
Bilici A., Olmez O. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., Cubukcu E., Sendur M. A. N., Aksoy S., Erdem D., et al.
Acta oncologica (Stockholm, Sweden), pp.1-10, 2023 (SCI-Expanded)
- VII. **Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group**
DOĞAN İ., AKSOY S., ÇAKAR B., BAŞARAN G., Ercelep O., Mandel N. M., KORKMAZ T., Gokmen E., ŞENER C., AYDINER A., et al.
CANCERS, no.6, 2023 (SCI-Expanded)
- VIII. **Alpelisib induced interstitial lung disease in a patient with advanced breast cancer**
Isiklar A., Basaran G., Sepin B., Gumusay Ö., Kocagoz A. S., Cuhadaroglu Ç.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.29, no.2, pp.484-488, 2023 (SCI-Expanded)
- IX. **What Has Changed in Patients Aged 65 and over Diagnosed with Breast Cancer during the COVID-19 Pandemic: A Single-Center Experience**
Soyder A., GÜLDOĞAN N., Isiklar A., Aribal E., Başaran G.
BREAST CARE, vol.17, no.4, pp.385-390, 2022 (SCI-Expanded)
- X. **Clinical outcome and characteristics of Turkish breast cancer patients during SARS-Cov-2 pandemic: Single center experience.**
Isiklar A., Soyder A., Gümüşay Ö., Basaran G.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16_suppl, pp.1-5, 2022 (SCI-Expanded)
- XI. **Sentinel lymph node biopsy with/without axillary dissection in clinically node-positive breast cancer after neoadjuvant chemotherapy**
CABIOĞLU N., KARANLIK H., Gulcelik M. A., Ilgun S., Igci A., URAS C., Cakmak G. K., UĞURLU M. Ü., Muslumanoglu M., Kocer H. B., et al.
ANNALS OF SURGICAL ONCOLOGY, vol.29, no.SUPPL 1, pp.69-70, 2022 (SCI-Expanded)
- XII. **Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study**
Bilici A., Uysal M., Menekse S., Akin S., Yildiz F., Turan M., SEZGİN GÖKSU S., Beypinar I., Sakalar T., Degirmenci M., et al.
CANCER INVESTIGATION, vol.40, no.2, pp.199-209, 2022 (SCI-Expanded)
- XIII. **Clinical and pathologic characteristics of Turkish breast cancer (BC) patients screened with BRCA1, BRCA2 or 26-gene inherited cancer panel testing: Single institution experience**
Isiklar A., Soyder A., YARARBAŞ K., Ekmekci C., Yazici H., BAŞARAN G.
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XIV. **Approach to Breast Cancer Treatment in Elderly Patients**
Seber S., ÇABUK D., BAŞARAN G.
TIBBİ ONKOLOJİ - GERIATRİK ONKOLOJİ, vol.20, pp.77-87, 2020 (SCI-Expanded)
- XV. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-**

positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Guler E. N., et al.
Balkan medical journal, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)

- XVI. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial.**
Demir A., Molinas Mandel N., Paydaş S., Demir O. G., Er Ö., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Güler E. N., et al.
Balkan Medical Journal, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)
- XVII. **Pembrolizumab for Early Triple-Negative Breast Cancer**
Schmid P., Cortes J., Pusztai L., McArthur H., Kuemmel S., Bergh J., Denkert C., Park Y. H., Hui R., Harbeck N., et al.
NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.9, pp.810-821, 2020 (SCI-Expanded)
- XVIII. **Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes**
Esin E., Oksuzoglu B., Bilici A., ÇİÇİN İ., KÖSTEK O., Kaplan M. A., AKSOY S., AKTAŞ B. E., Ozdemir O., Alacacioglu A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.1, pp.131-143, 2019 (SCI-Expanded)
- XIX. **Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer**
Basaran G., Twelves C., Dieras V., Cortes J., Awada A.
CANCER TREATMENT REVIEWS, vol.63, pp.144-155, 2018 (SCI-Expanded)
- XX. **COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY**
Altundag K., Basaran G., Oksuzoglu B., Oven B., ÖZGÜROĞLU M., Aydin D., Hacibedel B., Helvacioğlu K., Tuna E., Tatar M.
VALUE IN HEALTH, no.3, 2016 (SCI-Expanded)
- XXI. **Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials**
Korkmaz T., Seber S., Basaran G.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.98, pp.180-188, 2016 (SCI-Expanded)
- XXII. **A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)**
Tryfonidis K., Basaran G., Bogaerts J., Debled M., Dirix L., Thery J., Tjan-Heijnen V. C. G., Van den Weyngaert D., Cufer T., Piccart M., et al.
EUROPEAN JOURNAL OF CANCER, vol.53, pp.144-154, 2016 (SCI-Expanded)
- XXIII. **Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)**
Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., SAİP P. M., Dogu G. G., Eralp Y., Uslu R., Sevinc A., et al.
BREAST CANCER, vol.22, no.5, pp.480-485, 2015 (SCI-Expanded)
- XXIV. **Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer**
Iyikesici M. S., BAŞARAN G., DANE F., Ekenel M., YUMUK P. F., ÇABUK D., Teomete M., Turhal N. S.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.7, no.5, pp.1459-1464, 2014 (SCI-Expanded)
- XXV. **Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience**
Cabuk D., BAŞARAN G., Teomete M., Dane F., Korkmaz T., Seber S., Telli F., Yumuk P. F., Turhal S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.1, pp.117-122, 2014 (SCI-Expanded)
- XXVI. **Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial**
SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., Benekli M., Kucukoner M., Isikdogan A., Un O., et al.

BREAST, vol.22, no.5, pp.628-633, 2013 (SCI-Expanded)

- XXVII. **Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer**
Korkmaz T., Seber S., Okutur K., BAŞARAN G., Yumuk F., Dane F., ÖNEŞ T., Polat O., Madenci O. C., Demir G., et al.
BIOMARKERS, vol.18, no.1, pp.88-94, 2013 (SCI-Expanded)
- XXVIII. **Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.**
Dane F., Atasoy B. M., Akgun Z., Yumuk F., Cabuk D., Teomete M., Basaran G., Turhal S., Abacioglu U.
JOURNAL OF CLINICAL ONCOLOGY, vol.30, no.15_suppl, pp.16015, 2012 (SCI-Expanded)
- XXIX. **5-Flourouracil-Induced Encephalopathy in Parkinson's Disease**
Korkmaz T., Seber S., BAŞARAN G., Yumuk P. F., Dane F., Kocar M., Telli F., Turhal N. S.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.51-53, 2012 (SCI-Expanded)
- XXX. **The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study.**
Saip P., Keskin S., Ozkan M., Kaplan M. A., Aydogan F., Gonullu Demirag G., Uzunoglu S., Engin H., Basaran G., Guler N., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.16, no.4, pp.664-71, 2011 (SCI-Expanded)
- XXXI. **Clinical outcome of breast cancer patients with N3a (≥ 10 positive lymph nodes) disease: has it changed over years?**
BAŞARAN G., Devrim C., Caglar H. B., GÜLLÜOĞLU M. B., KAYA H., Seber S., Korkmaz T., Telli F., Kocak M., Dane F., et al.
MEDICAL ONCOLOGY, vol.28, no.3, pp.726-732, 2011 (SCI-Expanded)
- XXXII. **Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey**
BAŞARAN G., Turhal N. S., Cabuk D., Yurt N., Yurtseven G., Gumus M., Teomete M., Dane F., Yumuk P. F.
MEDICAL ONCOLOGY, vol.28, no.2, pp.409-415, 2011 (SCI-Expanded)
- XXXIII. **Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)**
Korkmaz T., Seber S., BAŞARAN G., Yumuk P. F., Dane F., Okutur K., Kanitez M., Kocar M., Telli F., Demir G., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- XXXIV. **The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK)**
AKBULUT H., Altundag M. K., SAİP P. M., Coskun H. S., Camci C., Ozkan M., Paydas S., Zengin N., Alco G., Aliustaoglu M., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- XXXV. **Clinical/pathologic characteristics of diabetic patients with early breast cancer (BC) and their survival outcome**
Seber S., BAŞARAN G., Korkmaz T., Telli F., Kocar M., Kanitez M., Dane F., Yumuk P. F., Turhal N. S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- XXXVI. **Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)**
Korkmaz T., Seber S., BAŞARAN G., Yumuk P. F., Dane F., Okutur K., Kanitez M., Kocar M., Telli F., Demir G., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- XXXVII. **Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer**
SAİP P. M., Eralp Y., Ozkan M., Karaca H., Benekli M., Cetin B., Isikdogan A., Kucukoner M., BAŞARAN G., Sen F., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- XXXVIII. **Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.**
Canhoroz M., Korkmaz T., Seber S., Bilici A., Okutur K., Toptas T., BAŞARAN G., Dede F., Yumuk F., Dane F., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- XXXIX. **The impact of 21-gene recurrence score (RS) scores on treatment decisions: Retrospective**

evaluation in Turkish early-stage breast cancer (BC) patients

BAŞARAN G., Saglam S., Tansan S., Demirel M., Gokmen E., Aktan S., Goker E., Kaban K. K., SAİP P. M., Demir G., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)

- XL. **Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.**
Icli F., Altundag K., Coskun U., Paydas S., BAŞARAN G., SAİP P. M., Dogu G. G., Eralp Y., Uslu R., Sevinc A., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- XLII. **Efficacy, safety and prognostic features of resected colon carcinoma treated in "real world" practice: a retrospective cohort-study**
Dane F., Ozturk M. A., Gumus M., Guven A., ALİUSTAOĞLU M., Cabuk D., Teomete M., BAŞARAN G., Yumuk P. F., Turhal N. S.
JOURNAL OF BUON, vol.16, no.2, pp.257-264, 2011 (SCI-Expanded)
- XLIII. **Primary breast mantle cell lymphoma with atypical relapse patterns.**
Dane F., Seker M., Fulden Yumuk P., Gunduz F., Peker O., Basaran G., Serdar Turhal N.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.16, no.1, pp.181-2, 2011 (SCI-Expanded)
- XLIV. **Pulmonary toxicity in patients receiving docetaxel chemotherapy**
Yumuk P. F., KEFELİ U., CEYHAN B., Dane F., Eroglu B. T., Gumus M., Cabuk D., BAŞARAN G., ABACIOGLU M. U., Turhal N. S.
MEDICAL ONCOLOGY, vol.27, no.4, pp.1381-1388, 2010 (SCI-Expanded)
- XLV. **Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?**
BAŞARAN G., Agaoglu F., BAŞARAN M.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.27, 2010 (SCI-Expanded)
- XLVI. **Weight gain after adjuvant chemotherapy in early breast cancer patients in Istanbul.**
Turhal N. S., BAŞARAN G., Yurt N., Yurtseven G., Cabuk D., Teomete M., Gumus M.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- XLVII. **How much do Turkish women know about breast cancer prevention?**
Basaran G., Yilmaz D., Bingol I., Kizlitac U.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- XLVIII. **The association between individual attachment patterns, the perceived social support, and the psychological well-being of Turkish informal caregivers**
Kuscu M. K., DURAL ŞENOĞUZ U., Oenen P., Yasa Y., Yayla M., Basaran G., Turhal S., BEKİROĞLU G. N.
PSYCHO-ONCOLOGY, vol.18, no.9, pp.927-935, 2009 (SCI-Expanded)
- XLIX. **A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion.**
Dane F., Ozturk M. A., Tecimer T., Atasoy B. M., Cabuk D., Yumuk P. F., Basaran G., Teomete M., Turhal N. S.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.14, no.2, pp.309-11, 2009 (SCI-Expanded)
- L. **Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer**
KEFELİ U., Dane F., Yumuk P. F., Karamanoglu A., Iyikesici S., Basaran G., Turhal N. S.
EUROPEAN JOURNAL OF CANCER CARE, vol.18, no.2, pp.191-194, 2009 (SCI-Expanded)
- LI. **Benefit from adjuvant anthracyclines according to hormone receptor status**
BAŞARAN G., Cabuk D., Teomete M., GÜLLÜOĞLU M. B., KAYA H., Dane F., Yumuk P. F., Turhal N. S.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- LII. **Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: Single institution experience**
Dane F., Gumus M., Ozturk M. A., Cabuk D., Atasoy M. B., Yumuk P. F., BAŞARAN G., Iyikesici M. S., Teomete M., ABACIOGLU M. U., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- LIII. **Clinical outcome of triple-negative (TN) breast cancer (BC)**
Cabuk D., BAŞARAN G., Kaya H., Gulluoglu B., Teomete M., Dane F., Yumuk P. F., Turhal N. S.

JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)

- LIII. **Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer**
Piccart-Gebhart M. J., Burzykowski T., Buyse M., Sledge G., Carmichael J., Lueck H., Mackey J. R., Nabholz J., Paridaens R., Biganzoli L., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.12, pp.1980-1986, 2008 (SCI-Expanded)
- LIV. **Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer**
Burzykowski T., Buyse M., Piccart-Gebhart M. J., Sledge G., Carmichael J., Lueck H., Mackey J. R., Nabholz J., Paridaens R., Biganzoli L., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.12, pp.1987-1992, 2008 (SCI-Expanded)
- LV. **Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial**
Pajk B., Cufer T., Canney P., Ellis P., Cameron D., Blot E., Vermorken J., Coleman R., Marreud S., Bogaerts J., et al.
BREAST, vol.17, no.2, pp.180-185, 2008 (SCI-Expanded)
- LVI. **Impact of body mass index on cancer development**
Yumuk P. F., Dane F., Yumuk V. D., Yazici D., Ege B., BEKİROĞLU G. N., TOPRAK A., Iyikesici S., BAŞARAN G., Turhal N. S.
JOURNAL OF BUON, vol.13, no.1, pp.55-59, 2008 (SCI-Expanded)
- LVII. **Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey**
Ustuner Z., BAŞARAN M., Dizdar Y., Agaoglu F., BİLGİÇ M. B., ŞAKAR B., BAŞARAN G., Darendeliler E., Ozger H., Onat H., et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol.213, no.3, pp.221-229, 2007 (SCI-Expanded)
- LVIII. **P2-323: Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey**
Yumuk P. F., Teomete M., Dane F., Cabuk D., Caglar H. B., Abacioglu U., Basaran G., Turhal N. S.
JOURNAL OF THORACIC ONCOLOGY, vol.2, no.8, pp.701, 2007 (SCI-Expanded)
- LIX. **Epithelioid hemangioendothelioma with multiple organ involvement**
Celikel C., Yumuk P. F., BAŞARAN G., Yildizeli B., Kodalli N., Ahiskali R.
APMIS, vol.115, no.7, pp.881-888, 2007 (SCI-Expanded)
- LX. **The role of adjuvant chemoradiotherapy (CRT) in Turkish patients with gastric carcinoma**
Gumus M., Dane F., Kaya S., Ozturk M. A., Yumuk P. F., Atasoy B. M., BAŞARAN G., Salepci T., Yaylaci M., Turhal N. S.
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)
- LXI. **Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital**
Dane F., GÜMÜŞ M., ÖZTÜRK A., Yumuk F., Iyikesici S., BAŞARAN G., Cabuk D., Teomete M., Turhal N. S.
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)
- LXII. **Clinical outcome of node-negative (NN) breast cancer (BC) patients**
BAŞARAN G., Cabuk D., Dane F., Teomete M., Iyikesici S., Meltem E., GÜLLÜOĞLU M. B., KAYA H., ABACIOGLU M. U., Yumuk F., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)
- LXIII. **Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer**
ATASOY B. M., ABACIOGLU M. U., Dane F., Ozgen Z., Yumuk P. F., Ozden S., Akgun Z., Mayadagli A., BAŞARAN G., Turhal S., et al.
JOURNAL OF BUON, vol.12, no.2, pp.203-208, 2007 (SCI-Expanded)
- LXIV. **Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: Relationship with pathological factors and prognostic impact on survival**
Cabuk D., BAŞARAN G., Celikel C., Dane F., Yumuk P. F., Iyikesici M. S., EKENEL M., Turhal N. S.
ONCOLOGY, vol.72, no.1-2, pp.111-117, 2007 (SCI-Expanded)

- LXV. **HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples**
Gumus M., Yumuk P. F., Salepci T., ALIUSTAOĞLU M., Dane F., EKENEL M., Basaran G., Kaya H., Barisik N., Turhal N. S.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.25, no.4, pp.515-521, 2006 (SCI-Expanded)
- LXVI. **Ewing's sarcoma of the rectum: Are four cycles of chemotherapy enough?**
ŞAKAR B., BAŞARAN G., BAŞARAN M.
JOURNAL OF CLINICAL ONCOLOGY, vol.23, no.24, pp.5849-5850, 2005 (SCI-Expanded)
- LXVII. **Chemoradiotherapy for localized non-Hodgkin's lymphoma: Lessons from old studies**
BAŞARAN G., BAŞARAN M., Onat H.
JOURNAL OF CLINICAL ONCOLOGY, vol.23, no.13, pp.3161-3162, 2005 (SCI-Expanded)
- LXVIII. **What is the optimal number of lymph nodes to be dissected in colorectal cancer surgery?**
Gumus M., Yumuk P., Atalay G., ALIUSTAOĞLU M., Macunluoglu B., Dane F., Caglar H., Sengoz M., Turhal S.
TUMORI JOURNAL, vol.91, no.2, pp.168-172, 2005 (SCI-Expanded)
- LXIX. **Does the incidence of anal canal cancers differ in Moslem societies?**
Yumuk P., ABACIOGLU M. U., Demir G., Cabuk D., Dane F., Gumus M., Ozguroglu M., EKENEL M., Basaran G., Turhal N.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol.20, no.1, pp.76, 2005 (SCI-Expanded)
- LXX. **The role of anti-CENP-B and anti-SS-B antibodies in breast cancer**
Atalay C., Atalay G., Yilmaz K., Altinok Y.
NEOPLASMA, vol.52, no.1, pp.32-35, 2005 (SCI-Expanded)
- LXXI. **D-dimer - Can it be a marker for malignant gastric lesions?**
ALIUSTAOĞLU M., Yumuk P., Gumus M., EKENEL M., Bolukbas F., Bolukbas C., Mutlu N., BAŞARAN G., Avsar E., Turhal N.
ACTA ONCOLOGICA, vol.43, no.8, pp.770-771, 2004 (SCI-Expanded)
- LXXII. **Remaining controversies in the upfront management of advanced ovarian cancer.**
Mano M., Awada A., Minisini A., Atalay G., Lago L., Cardoso F., Piccart M.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol.14, pp.707-20, 2004 (SCI-Expanded)
- LXXIII. **Attitude toward genetic testing for cancer risk in Istanbul**
Yumuk P., Gumus M., EKENEL M., BAŞARAN G., ALIUSTAOĞLU M., Topal A., Turhal N.
GENETIC TESTING, vol.8, no.2, pp.169-173, 2004 (SCI-Expanded)
- LXXIV. **What is the effect of systemic anticancer treatment on cognitive function?**
Minisini A., Atalay G., Bottomley A., Puglisi F., Piccart M., Biganzoli L.
LANCET ONCOLOGY, vol.5, no.5, pp.273-282, 2004 (SCI-Expanded)
- LXXV. **The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.**
Atalay G., Dirix L., Biganzoli L., Beex L., Nooij M., Cameron D., Lohrisch C., Cufer T., Lobelle J., Mattiacci M., et al.
Annals of oncology : official journal of the European Society for Medical Oncology, vol.15, pp.211-7, 2004 (SCI-Expanded)
- LXXVI. **Clinical outcome of breast cancer (BC) patients (pts) with pT1N0M0 disease**
BAŞARAN G., EKENEL M., Demirkalem P., Cakir T., GÜLLÜOĞLU M. B., Gumus M., Dane F., Iyikesici S., Yumuk F., Turhal S.
ANNALS OF ONCOLOGY, vol.15, pp.68, 2004 (SCI-Expanded)
- LXXVII. **Clinical features and adjuvant treatment outcomes of colon cancer (cc) in two outpatient populations of Knoxville, Tennessee and Istanbul, Turkey**
Dane F., Turhal N. S., Iyikesici S., Gumus M., Yumuk P. F., BAŞARAN G., EKENEL M., Avery B.
ANNALS OF ONCOLOGY, vol.15, pp.95, 2004 (SCI-Expanded)
- LXXVIII. **Treatment outcomes in non-small cell lung cancer (NSCLC) patients: Comparison between Marmara University, Istanbul, Turkey and Knoxville, Tennessee**
Iyikesici S., Turhal N. S., Yumuk P. F., Dane F., Gumus M., BAŞARAN G., EKENEL M., Avery B.

ANNALS OF ONCOLOGY, vol.15, pp.195-196, 2004 (SCI-Expanded)

- LXXXIX. **Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.**
Atalay G., Biganzoli L., Renard F., Paridaens R., Cufer T., Coleman R., Calvert A., Gamucci T., Minisini A., Therasse P., et al.
European journal of cancer (Oxford, England : 1990), vol.39, pp.2439-49, 2003 (SCI-Expanded)
- LXXX. **The pipeline of new anticancer agents for breast cancer treatment in 2003.**
Awada A., Cardoso F., Atalay G., Giuliani R., Mano M., Piccart M.
Critical reviews in oncology/hematology, vol.48, pp.45-63, 2003 (SCI-Expanded)
- LXXXI. **Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?**
Atalay G., Cardoso F., Paesmans M., Goldberg R., Bleiberg H.
Anti-cancer drugs, vol.14, pp.703-13, 2003 (SCI-Expanded)
- LXXXII. **Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.**
Atalay G., Cardoso F., Awada A., Piccart M.
Annals of oncology : official journal of the European Society for Medical Oncology, vol.14, pp.1346-63, 2003 (SCI-Expanded)
- LXXXIII. **An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.**
Bonnefoi H., Biganzoli L., Mauriac L., Cufer T., Schaefer P., Atalay G., Piccart M.
European journal of cancer (Oxford, England : 1990), vol.39, pp.1277-83, 2003 (SCI-Expanded)
- LXXXIV. **Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.**
Piccart M., Cardoso F., Atalay G.
European journal of cancer (Oxford, England : 1990), 2002 (SCI-Expanded)
- LXXXV. **Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.**
Di L., Cardoso F., Durbecq V., Giuliani R., Mano M., Atalay G., Larsimont D., Sotiriou C., Biganzoli L., Piccart M.
International journal of clinical oncology, vol.7, pp.245-53, 2002 (SCI-Expanded)
- LXXXVI. **The effects of nitric oxide donors and inhibitors on neutrophil functions in Behcet's disease**
Atalay G., Eksioğlu-Demiralp E., Akoglu T., DİRESKENELİ R. H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.20, no.4, 2002 (SCI-Expanded)
- LXXXVII. **Predictive factors associated with axillary lymph node metastasis(ALNM) in T1, T2 and T3 breast carcinomas**
Atalay G., Gumus M., Aliustaoglu M., Turhal N.
EUROPEAN JOURNAL OF CANCER, vol.38, 2002 (SCI-Expanded)
- LXXXVIII. **Progress in systemic therapy for breast cancer**
Piccart M., Cardoso F., Atalay G., Biganzoli L.
EUROPEAN JOURNAL OF CANCER, vol.38, 2002 (SCI-Expanded)
- LXXXIX. **Rectodynamic and radiological assessment in modified Mainz pouch II cases**
Gumus E., Miroglu C., Saporta L., Basaran G., Horasanli K., Tanriverdi O., Karadag H.
EUROPEAN UROLOGY, vol.38, no.3, pp.316-322, 2000 (SCI-Expanded)
- XC. **Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b**
Senturk H., Mert A., Akdogan M., TABAK Ö. F., Basaran G., Turkoglu S., Ozbay G., Badur S.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, vol.32, no.5, pp.575-576, 2000 (SCI-Expanded)
- XCI. **Endocarditis prophylaxis for transrectal prostatic biopsy**
Basaran G.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol.280, no.22, pp.1908, 1998 (SCI-Expanded)

Articles Published in Other Journals

- I. **Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer**
Işıklar A., Başaran G., Celayir O. M., Kahraman G., Somanje J., Çolak S. Ö., Serteser M., Tozun N.
Acibadem Üniversitesi Sağlık Bilimleri Dergisi, vol.14, no.3, pp.1-7, 2023 (Peer-Reviewed Journal)
- II. **Clinical Outcome and Characteristics of Turkish Breast Cancer Patients who had SARS-Cov-2 Infection**
Işıklar A., Zengin R., Balci V., Sesin Kocagöz A. S., BAŞARAN G.
Turk Onkoloji Dergisi, vol.37, no.4, pp.419-425, 2022 (ESCI)
- III. **How Do Breast Cancer Patients Present Following COVID-19 Early Peak in a Breast Cancer Center in Turkey?**
Isiklar A. D., Deniz C., Soyder A., Guldogan N., Yilmaz E., Basaran G.
EUROPEAN JOURNAL OF BREAST HEALTH, vol.17, no.3, pp.253-257, 2021 (ESCI)
- IV. **Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak**
Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., ERALP Y., Gulluoglu B. M.
TURKISH JOURNAL OF SURGERY, vol.36, no.2, pp.147-163, 2020 (ESCI)
- V. **The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience**
Eralp Y., Kilic L., Alco G., BAŞARAN G., Dogan M., Dincol D., Demirci S., Icli F., Onur H., SAİP P. M., et al.
JOURNAL OF BREAST HEALTH, vol.10, no.4, pp.209-215, 2014 (ESCI)
- VI. **Hipokalemik paralizisi ile klinik belirti veren adrenokortikal karsinom olgusu**
Salman S., Meriçliler Y. Ö., Başaran G.
Acibadem Üniversitesi Sağlık Bilimleri Dergisi, vol.4, pp.34-36, 2013 (Peer-Reviewed Journal)
- VII. **Prognostic role of initial PET CT SUV max value in metastatic gastric adenocarcinoma**
KORKMAZ T., ŞEBER E. S., OKUTUR S. K., CANHOROZ M., BİLİCİ A., TOPTAŞ T., BAŞARAN G., DEDE F., YUMUK P. F., DANE F., et al.
Mediterranean Oncology Journal, vol.1, no.2, pp.35-39, 2012 (Peer-Reviewed Journal)
- VIII. **OUTCOME OF LOCALLY ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS - MARMARA UNIVERSITY EXPERIENCE**
Yumuk P. F., Iyikesici M. S., Gümüş M., Aliustaoglu M., Dane F., Başaran G., Ekenel M., Abacioglu U.
Türk Onkoloji Dergisi, vol.19, no.3, pp.106-111, 2004 (Peer-Reviewed Journal)
- IX. **Neoplastic diseases prevalence in a Turkish university hospital.**
Turhal N. S., Aliustaoglu M., Gurses I., Gumus M., Atalay G., Karamanoglu A., Sengöz M.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.8, no.1, pp.45-8, 2003 (Scopus)

Books & Book Chapters

- I. **Meme Kanserinde Sistemik Onkolojik Tedaviler**
Başaran G. (Member Of Editors Board)
in: Meme Kanseri Cerrahisi ile Cerrahi Sonrası Tedavi Ve Onarımları - 2024 , Prof. Dr. Erol Benliler, Member Of Editors Board, Türkiye Klinikleri Yayınevi, İstanbul, pp.37-43, 2024
- II. **Metastatik meme kanserinde endokrin tedavi: Yeni ajanların Klinik pratiğimize etkisi**
Başaran G., Çabuk D.
in: HR+HER2- Meme Kanserinde Sistemik tedaviler ve güncel yaklaşımlar, Nil Molinas, Nilüfer Güler, Feyyaz Özdemir, İrfan Çiçin, Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.7-360, 2022
- III. **Yaşlı hastalarda meme kanseri tedavisine yaklaşım**
Çabuk D., Başaran G.
in: Geriatrik Onkoloji, KARAoğlu A, Işık AT, Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.1-134, 2020
- IV. **Adjuvant Therapy for HER-2-Positive Early Breast Cancer**

Başaran G., Çabuk D.

in: Breast Cancer, adnan aydiner,Abdullah İğci,Atilla Soran, Editor, Springer Nature, Basel, pp.1-824, 2019

V. **Kanser Hastalarında Fizik Muayene**

Başaran G., Çabuk D.

in: Kanser Hastasına YAKlaşım, Nil Molinas,Haluk Onat, Editor, Nobel Tıp Kitapevi, İstanbul, pp.1-563, 2012

VI. **Hematolojik ve non-hematolojik malinitelerde protokoller**

Başaran G., Atasoy B. M., Atagündüz I., Abacıoğlu M. U., Çetiner M., Kocakaya O.

in: Hematolojik ve non-hematolojik malinitelerde protokoller, Mustafa Çetiner, Editor, Yelken Basım Yayım, İstanbul, pp.1-159, 2007

VII. **Node-positive breast cancer**

Atalay G., Lohrisch C., Piccart M.

in: Breast cancer management, KAtia Tonkin,David M Reese,MAtti S Aapro,Aman A Buzdar, Editor, Lippincott Williams & Wilkins , Pennsylvania, pp.3-603, 2003

Refereed Congress / Symposium Publications in Proceedings

- I. **Combined Analysis of the MF18-02/03 Neosentitürk Studies: Factors Predicting Recurrence in ycN0/ypN-positive Breast Cancer with Sentinel Lymph Node Biopsy - Or Targeted Axillary Dissection - Alone After Neoadjuvant Chemotherapy**
CABIOĞLU N., Muslumanoglu M., İgci A., KARANLIK H., TÜKENMEZ M., Gulcelik M. A., Kocer H. B., Cakmak G. K., Yildirim N., EMİROĞLU S., et al.
24th Annual Meeting of The American Society of Breast Surgeons (ASBrS), Mississippi, United States Of America, 26 - 30 April 2023
- II. **Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group**
Eralp Y., Dogan I., AKSOY S., Cakar B., Basaran G., Ercelep O., Molinas Mandel N., Korkmaz T., Gokmen E., Aydiner A., et al.
San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 6 - 10 December 2022
- III. **AXILLARY NODAL RECURRENCE IS RARE IN PATIENTS WITH NODE-POSITIVE BREAST CANCER UNDERGOING SLNB FOLLOWING NEOADJUVANT CHEMOTHERAPY : EARLY RESULTS OF THE NEOSENTITURK-TRIAL/MF-18-03**
Cabioglu N., KARANLIK H., Gulcelik M. A., İgci A., Muslumanoglu M., Kocer H. B., Uras C., Akgul G. G., TÜKENMEZ M., Ilgun S., et al.
San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 6 - 10 December 2022
- IV. **Clinical outcome and characteristics of Turkish breast cancer patients during SARSCov-2 pandemic: Single center experience.**
Isoklar A., Soyder A., Gumusay O., Basaran G.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022
- V. **Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).**
Bilici A., Olmez O. F., Sezer A., Oksuzoglu B., Kaplan M. A., Karadurmus N., Cubukcu E., ŞENDUR M. A. N., AKSOY S., Erdem D., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022
- VI. **The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey molecular profiling in advanced cancers trial (TUMPACT)**
Olmez O. F., Bilici A., ER O., Sevinc A., Akman T., Uslu R., Mandel N. M., YALÇIN Ş., Teomete M., Gorumlu G., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- VII. **Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey**

Başaran G., Demirci U., Yıldız F., Çiçin İ., Aktaş B. Y., Öztürk B., Sezgin Göksu S., Coşkun H. Ş., Oyan Uluç B., Sönmez Ö., et al.

American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, United States Of America, 29 - 31 May 2020, pp.13055

- VIII. **Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.**
Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., Goksu S. S., Coskun H. S., Oyan B., Sonmez O., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38
- IX. **Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey**
Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., Kostek O., Turhal S., PAYDAŞ S., Topcu S., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 14 December 2019, vol.80
- X. **Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results**
Esin E., Oksuzoglu O. B. C., Bilici A., ÇİÇİN İ., AKSOY S., Alacacioglu A., Kaplan M. A., ÇABUK D., Sumbul A. T., PAYDAŞ S., et al.
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.104-105
- XI. **TÜRKİYE'DE METASTATİK MEME KANSERİNDE HER2 HEDEFLİTEDAVIDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLİLİKVERİLERİ**
ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., OLGUN P., ŞAKALAR T., AKTAŞ B. Y., DEĞİRMENCİOĞLU S., et al.
7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 24 March 2018
- XII. **High Ki67 levels are significantly correlated with 21-gene assay recurrence scores**
Uras C., Boler D. E., Kara H., Basaran G., Balci L., Tokat F., Cabioglu N., Ince Ü.
10th European Breast Cancer Conference (EBCC), Amsterdam, Netherlands, 9 - 11 March 2016, vol.57
- XIII. **Mutation analysis of the BRCA1 and BRCA2 genes in Turkish patients with breast cancer.**
Apeessos A., Tsoulos N., Papadopoulou E., Metaxa-Mariatou V., Agiannitopoulos K., Tansan S., Irgil C., Gokmen E., Cakmakci M., Basaran C., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIV. **Prognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).**
Basaran G., Korkmaz T., Kara H., Boler D., Kapucuoglu N., Uras C., Saglican Y., Ince Ü.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XV. **Prognostic role of progesterone receptor expression by immunohistochemistry in relation to oncotype recurrence scores**
KORKMAZ T., BAŞARAN G., KAPUCUOĞLU N., SAĞLİCAN Y., BEŞE N., İÇTEN G. E., URAS C., İNCE Ü.
international İstanbul Breast Cancer Conference, İstanbul, Turkey, 30 September - 02 October 2014
- XVI. **Systemic ritoximab immunotherapy in the management of primary ocular adnexal lymphoma: Slagle institution experience.**
Tuncer S., Basaran M., Tanyildiz B., Buyukbabani N., Basaran G., Dogan O.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XVII. **Clinical and pathologic characteristics of patients with breast cancer and a second non-breast primary tumor.**

Basaran G., Yazar A., Uras C., Tezcanli E., Cabuk D., Atalar B., Ozyar E.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

- XVIII. **Kişiyeye özel meme kanseri tedavisinde ki67 oranlarının Oncotype Dx skorlarıyla korelasyonu**
URAS C., CABIOĞLU N., TOKAT F., BAŞARAN G., ER YAZAR Ö., BÖLER D., ATALAR B., BEŞE N., İNCE Ü.
18. Ulusal Cerrahi kongresi, İzmir, Turkey, 23 - 27 May 2012
- XIX. **Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.**
Dane F., Atasoy B. M., Akgun Z., Yumuk F., Cabuk D., Teomete M., BAŞARAN G., Turhal S., ABACIOGLU M. U.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XX. **High Ki67 Values Are Significantly Correlated with Oncotype DX Scores**
URAS C., CABIOĞLU N., Tokat F., BAŞARAN G., Boler D., ATALAR B., ER O., Bese N., İNCE Ü.
8th European Breast Cancer Conference (EBCC), Vienna, Austria, 21 - 24 March 2012, vol.48
- XXI. **Taxanes as adjuvant therapy for breast cancer**
BAŞARAN G.
European Breast Cancer Conference, Barcelona, Spain, 24 March 2010, vol.8, pp.17
- XXII. **Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities. Single center experience**
Cabuk D., BAŞARAN G., Korkmaz T., Seber S., Dane F., Telli F., Yumuk F., Turhal N. S.
European Breast Cancer Conference, Barcelona, Spain, 24 March 2010, vol.8, pp.205
- XXIII. **Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology Group Study**
BAŞARAN G., Okkan S., Caglar H., Benekli M., Gumus M., Haydaroglu A., Eralp Y., Abali H., Yildiz F., Bese N., et al.
32nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 13 December 2009, vol.69
- XXIV. **Pulmonary toxicity in patients receiving docetaxel chemotherapy**
Kefeli U., Yumuk P. F., CEYHAN B., Dane F., Eroglu B., Cabuk D., BAŞARAN G., Teomete M., Turhal N. S.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- XXV. **Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)**
Yumuk P. F., Teomete M., Dane F., Cabuk D., BAŞARAN G., Turhal N. S.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- XXVI. **Results of randomized phase II trial combining Iressa (R) (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021.**
Mauriac L., Cameron D., Dirix L., Blot E., Piccart M., Marreaud S., Tjan-Heijnen V., Cufer T., Bogaerts J., Basaran A. G.
31st Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 10 - 14 December 2008, vol.69
- XXVII. **Memenin Apokrin Karsinomunda Hormon Reseptörleri ve Onkogenlerin Ekspresyonu**
ERBARUT İ., KAYA H., BAŞARAN G., GÜLLÜOĞLU M. B.
17. Ulusal Patoloji Sempozyumu, Turkey, 1 - 06 October 2004
- XXVIII. **Interstitial pneumonitis associated with docetaxel administration**
Dane F., Topaloglu N., Abul Y., Yumuk P. F., Turhal N. S., Ceyhan B., Celikel T., Caglar H., BAŞARAN G., Ahiskali R.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.307
- XXIX. **Outcome of metastatic colorectal cancer patients receiving palliative chemotherapy in Marmara University Hospital**
Dane F., Yumuk F., Gumus M., Iyikesici S., Tufan A., BAŞARAN G., Cabuk D., Teomete M., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006,

vol.17, pp.129

- XXX. **Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey**
Teomete M., Yumuk P. F., Iyikesici M. S., Dane F., Basaran G., Cabuk D., Caglar H. B., Abacioglu U., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.225-226
- XXXI. **Association between presence of HPV DNA and P53 in breast cancer patients**
Yumuk P. F., Gumus M., Kaya H., Alam K., Dane F., Gulluoglu B., Salepci T., Barisik N., BAŞARAN G., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.110-111
- XXXII. **Outcome of adjuvant treatment in turkish breast cancer (BC) patients (PTS): Single institution experience**
Cabuk D., BAŞARAN G., Iyikesici S., EKENEL M., Dane F., Teomete M., Gumus M., Aliustaoglu M., Yumuk F., Turhal S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.109
- XXXIII. **Outcome of colon cancer patients receiving adjuvant chemotherapy in Marmara University Hospital**
Dane F., Gumus M., Yumuk P. F., Iyikesici S., Ozturk A., BAŞARAN G., Caglar H. B., Cabuk D., Teomete M., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.130
- XXXIV. **Stage I (T1N0M0) breast cancer (BC): Pathological characteristics and clinical outcome**
BAŞARAN G., Cabuk D., Caglar H. B., Iyikesici S., Tebessum C., Gulluoglu B., Kaya H., Dane F., Yumuk P. F., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.113
- XXXV. **Trastuzumab beyond progression in metastatic breast cancer**
Yanmaz M. T., Ozguroglu M., Ozturk B., Uygun K., BAŞARAN G., TURNA Z. H., Yildiz O., Baran A., Demir G., Buyukunal E.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.77
- XXXVI. **Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study**
BAŞARAN G., Guney N., SAİP P. M., Iyikesici S., Kaya H., YAZICI H., Serdar T. N.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.90-91
- XXXVII. **Outcome of adjuvant treatment in elderly Turkish breast cancer patients.**
EKENEL M., BAŞARAN G., Dane F., Iyikesici S., Yumuk F., Turhal S.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XXXVIII. **The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).**
Iyikesici M., KEFELİ U., BAŞARAN G., Dane F., EKENEL M., Yumuk P., Turhal N.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XXXIX. **VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with pathological factors and prognostic impact on survival.**
Cabuk D., BAŞARAN G., Yumuk P., Celikel C., Dane F., Iyikesici M., EKENEL M., Turhal N.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XL. **Clinical and pathological characteristics of early breast cancer (EBC) patients < 35 years old.**
BAŞARAN G., Dane F., Iyikesici S., EKENEL M., Yumuk F., Turhal S.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23

- XLI. A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer**
Burzykowski T, Piccart M, Sledge G., Carmichael J., Luck H., Mackey J., Nabholz J., Paridaens R., Biganzoli L., Jassem J., et al.
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 8 - 11 December 2005, vol.94
- XLII. Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: an analysis of 4,256 patients randomized in 12 trials**
Piccart M., Burzykowski T., Sledge G., Carmichael J., Luck H., Mackey J., Nabholz J., Paridaens R., Biganzoli L., Jassem J., et al.
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 8 - 11 December 2005, vol.94
- XLIII. FOLFOX4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 5-FU/irinotecan based combination regimens.**
Dane F., Yumuk P., Turhal N., Ekenel M., Basaran G., Iyikesici M., Tecimer C.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XLIV. The expression pattern of members of the EGFR signaling pathway and its relation with the duration of response in metastatic breast cancer (BC) patients (pts) treated with endocrine therapy (ET)**
Atalay G., Durbecq V., Larsimont D., Rouas G., Di Leo A., Leroy J., Piccart M.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XLV. Human papilloma virus: Is it a new etiological factor in breast cancer?**
Gumus M., Yumuk F., Salepci T., Aliustacglu M., EKENEL M., BAŞARAN G., Dane F., Kaya H., Barisik N., Turhal N.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XLVI. Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer patients' tumors.**
Aliustaoglu M., Gumus M., Midi A., Celikel C., EKENEL M., Yumuk F., BAŞARAN G., Turhal N.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XLVII. Is the incidence of anal canal cancers different in Moslem societies?**
Cabuk D., Yumuk P., ABACIOGLU M. U., Demir G., Dane F., Gumus M., Ozguroglu M., EKENEL M., BAŞARAN G., Turhal N.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XLVIII. An EORTC IDBBC-ECSG randomized phase II trial of two different schedules of Caelyx (TM) in metastatic breast cancer patients.**
Coleman R., Biganzoli L., Canney P., Mauriac L., Dirix L., Chollet P., Atalay G., Johnston S., Dittrich C., Piccart M.
25th San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 11 - 14 December 2002, vol.76
- XLIX. Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era.**
Atalay G., Biganzoli L., Renard F., Paridaens R., Batter V., Coleman R., Piccart M., Calvert A., Gamucci T., Cofer T.
25th San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 11 - 14 December 2002, vol.76

Supported Projects

Başaran G., Gümüşay Ö., Project Supported by Private Organizations in Other Countries, Erken evre meme kanserinde prognozu belirlemede CAnassist testi ile Mammaprint/ OncotypeDx testleri arasında konkordans, 2022 - 2023

Işıklar A., Başaran G., Soyder A., Gümüşay Ö., Project Supported by Higher Education Institutions, COVID-19 geciren meme kanseri hastalarının özellikleri ve hastalığın seyri, 2021 - 2022

Başaran G., Tözün A. N., Işıklar A., Öykü Çolak S., Jameela Somanje C., Kahraman G., Project Supported by Higher Education Institutions, COVID aşılarının meme kanseri hastalarında klinik etkileri ve oluşun bağışıklık yanıtı, 2021 - 2022

Scientific Refereeing

Meme Sağılı Dergisi Sayı:1556 Bir Ön Çalışma: Meme Kanseri Dokusunun ve Aksiller Metastatik Lenf Nodunun Proteomik Profillenmesi, Other Journals, October 2012

Scientific Consultations

ESMO, Project Consultancy, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, Turkey, 2020 - Continues

Metrics

Publication: 158

Citation (WoS): 1884

Citation (Scopus): 2435

H-Index (WoS): 18

H-Index (Scopus): 18

Congress and Symposium Activities

11. Türk Tıbbi Onkoloji Kongresi, Invited Speaker, Girne, Cyprus (Kkctc), 2024

BEYNÖLXALQ KONFRANS, Attendee, Baku, Azerbaijan, 2024

7. Karadeniz Meme Kongresi, Session Moderator, Samsun, Turkey, 2024

KİD A'dan Z'ye İmmüno-Onkolojik Tedaviler Kursu, Moderator, İstanbul, Turkey, 2024

Kanserde Güncel Gelişmeler 2024 - Meme Kanseri Tedavisinde Yenilikler Sempozyumu, Invited Speaker, Kayseri, Turkey, 2024

Marmara Onkoloji Derneğı 4. Meme Kanseri Senpozyumu, Moderator, İstanbul, Turkey, 2024

Marmara Onkoloji Derneğı 4. Meme Kanseri Senpozyumu, Invited Speaker, İstanbul, Turkey, 2024

TOG - Temel Bilimlerden Klinik Bilimlere Araştırma Toplantıları, Invited Speaker, İstanbul, Turkey, 2024

16. Meme Kanseri Yeni Yaklaşımlar, Invited Speaker, İstanbul, Turkey, 2024

Multidisipliner Meme Kanseri Konseyi, Moderator, İstanbul, Turkey, 2023

Florence Nightingale Demiroğlu Bilim Üniversitesi 12. Onkoloji Günleri, Invited Speaker, İstanbul, Turkey, 2023

6. Gençlerle Onkolojiye Bakış Kongresi, Moderator, Antalya, Turkey, 2023

II. International Baku Breast Cancer Congress, Invited Speaker, Baku, Azerbaijan, 2023

LİV HOSPİTAL Meme Kanseri Genetiğı ve Genomikleri, Invited Speaker, İstanbul, Turkey, 2023

Türk Tıbbi Onkoloji Derneğı , Invited Speaker, İstanbul, Turkey, 2023

İMAG 41. Olgu Toplantısı, Moderator, İstanbul, Turkey, 2023

8. Karadeniz Onkoloji Günleri, Moderator, Trabzon, Turkey, 2023

Her Yönüyle Kadıyla , Invited Speaker, İstanbul, Turkey, 2023

Novartis Medikal Danışma Kurulu , Attendee, İstanbul, Turkey, 2023

ON∞ TARGET, Session Moderator, Trabzon, Turkey, 2023

21st Sis World Congress on Breast Cancer and Breast Healthcare, Invited Speaker, Rodos, Greece, 2023

10. Türk Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2023

Hedef Kanseri 2023, Invited Speaker, Girne, Cyprus (Kkct), 2023
2023 St. Gallen Meme Kanseri Sempozyumu, Panelists, İstanbul, Turkey, 2023
2023 St. Gallen Meme Kanseri Sempozyumu, Invited Speaker, İstanbul, Turkey, 2023
6. Karadeniz Meme Kongresi, Moderator, Samsun, Turkey, 2023
Kanserde Güncel Gelişmeler 2023, Meme Kanseri Tedavisinde Yenilikler Sempozyumu, Panelists, İstanbul, Turkey, 2023
KANSERDE GÜNCEL GELİŞMELER 2023, MEME KANSERİ TEDAVİSİNDE YENİLİKLER SEMPOZYUMU, Panelists, İstanbul, Turkey, 2023
Meme Kanseri 2023 Güncel Tedavi Yaklaşımları Sempozyumu, Session Moderator, İstanbul, Turkey, 2023
Meme Kanseri 2023 Güncel Tedavi Yaklaşımları Sempozyumu, Session Moderator, İstanbul, Turkey, 2023
St Luke's Canser Institute Postgraduate Symposium 2023, Invited Speaker, Los Banos, Philippines, 2023
15. Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2023
MEME KANSERİ OKULU TOPLANTILARI, Invited Speaker, İstanbul, Turkey, 2022
MEME KANSERİNDE GÜNCEL GELİŞMELER, Invited Speaker, İstanbul, Turkey, 2022
2022 SAN ANTONIO BREAST CANCER SYMPOSIUM, Attendee, Texas, United States Of America, 2022
ACUTBAT ONKOLOJİ SEMPOZYUMU, Invited Speaker, İstanbul, Turkey, 2022
EILEEN ARAŞTIRMACI TOPLANTISI, Attendee, İstanbul, Turkey, 2022
Erken Farket, Hayata Bağlan, Invited Speaker, İstanbul, Turkey, 2022
6. Ulusal İmmünoterapi ve Onkoloji Kongresi, Session Moderator, Antalya, Turkey, 2022
BREASTANBUL 2022, Invited Speaker, İstanbul, Turkey, 2022
BREASTANBUL 2022, Invited Speaker, İstanbul, Turkey, 2022
BREASTANBUL 2022, Panelists, İstanbul, Turkey, 2022
Meme Okulu, Moderator, İstanbul, Turkey, 2022
YULAREB DANIŞMA KURULU, Invited Speaker, İstanbul, Turkey, 2022
16. ULUSAL MEME HASTALIKLARI KONGRESİ, Invited Speaker, Lefkoşa, Cyprus (Kkct), 2022
TNBC patient journey: Challenges and solutions, Invited Speaker, Lebap, Turkmenistan, 2022
BEST OF ASCO 2022, Session Moderator, İstanbul, Turkey, 2022
5 th PRİMO Practical Recommendations in Immuno&Molecular Oncology, Invited Speaker, İstanbul, Turkey, 2022
HR+ İLERİ EVRE METASTATİK MEME KANSERİNİN TEDAVİSİNDE FULVESTRANT İLE 20. YIL, Invited Speaker, İstanbul, Turkey, 2022
ON TARGET MOLEKÜLER ONKOLOJİ, Moderator, İstanbul, Turkey, 2022
7. Karadeniz Onkoloji Günleri Mentör Önerileri Oturum , Moderator, Trabzon, Turkey, 2022
Onkolojide Yeni Tedavi Yaklaşımları Danışma Kurulu Toplantısı, Attendee, Hatay, Turkey, 2022
AKOD Meme Kansei Tedavisinde Anti-Estrogen Tedavinin Gücünü Arttırmak, Invited Speaker, İstanbul, Turkey, 2022
5. GENÇLERLE ONKOLOJİYE BAKIŞ KONGRESİ, Invited Speaker, İstanbul, Turkey, 2022
Meme Kanseri Tedavisinde Yenilikler Sempozyumu, Moderator, Kayseri, Turkey, 2022
The 6th International Clinical Oncology Congress, Invited Speaker, Tehran, Iran, 2022
Alpelisib Danışma Kurulu Toplantısı, Attendee, İstanbul, Turkey, 2022
2. Ulusal Meme Kanseri Sempozyumu, Invited Speaker, İstanbul, Turkey, 2022
ON TARGED Luminal-Erken Evre Meme Kanseri, Invited Speaker, Antalya, Turkey, 2022
14. Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı , Invited Speaker, İstanbul, Turkey, 2022
7. Onkolojide Güncel Gelişmeler Sempozyumu, Invited Speaker, İstanbul, Turkey, 2021
Web Targed Kongreden Bildiriyorum , Moderator, İstanbul, Turkey, 2021
8. Türk Tıbbi Onkoloji Kongresi, Moderator, Antalya, Turkey, 2021
Herzuma Danışma Kurulu Toplantısı , Attendee, İstanbul, Turkey, 2021
Meme Kanseri Kursu, Moderator, İstanbul, Turkey, 2021
IREBS 2021, Panelists, İstanbul, Turkey, 2021
HR+ Premenopozal Meme Kanseri Güncel Gelişmeler, Moderator, İstanbul, Turkey, 2021
Uluslararası Katılımlı 3. Ulusal Meme Cerrahisi Kongresi , Invited Speaker, İstanbul, Turkey, 2021
Hedef Kanseri , Moderator, İstanbul, Turkey, 2021
Acıbadem Üniversitesi Tıp Fakültesi Kampüs Buluşmaları, Invited Speaker, İstanbul, Turkey, 2021
İzmir Katip Çelebi Üniversitesi Öğrenci Bilim Kongresi , Invited Speaker, İzmir, Turkey, 2021

Biyobelirteçler ve Onkolojik Tedaviler , Invited Speaker, İstanbul, Turkey, 2021

Türk Tıbbi Onkoloji Derneği Online Toplantı , Invited Speaker, İstanbul, Turkey, 2021

Memorial Bilimsel Toplantıları – 5 , Invited Speaker, İstanbul, Turkey, 2021

Meme Kanseri 2021 Güncel Tedavi Yaklaşımları Sempozyumu , Invited Speaker, İstanbul, Turkey, 2021

4. Gençlerle Onkolojiye Bakış Kongresi, Moderator, İstanbul, Turkey, 2021

Meme Sempozyumu, Invited Speaker, İstanbul, Turkey, 2021

Türk Tıbbi Onkoloji Derneği , Invited Speaker, İstanbul, Turkey, 2021

ONCOLOGY HIGHLIGHTS 2020 , Invited Speaker, İstanbul, Turkey, 2021

San Antonio Breast Cancer Symposium, Attendee, Texas, United States Of America, 2020

WebTarged Onkolojinin Multidisipliner Platformu , Invited Speaker, İstanbul, Turkey, 2020

Prostat ve Meme Kanseri Tedavisinde 3'te 3 , Panelists, İstanbul, Turkey, 2020

ELEVATE 4, Invited Speaker, İstanbul, Turkey, 2020

Türk Tıbbi Onkoloji Derneği Sanal Kongresi, Panelists, İstanbul, Turkey, 2020

İmmünoterapi 2020, Invited Speaker, İstanbul, Turkey, 2020

SUWEN ve Pi Kadın Kanseri Derneği , Invited Speaker, İstanbul, Turkey, 2020

IREBS (Istanbul Reconstructive Breast Cancer Surgery Workshop) 2020 , Panelists, İstanbul, Turkey, 2020

ESMO 2020 , Invited Speaker, Barcelona, Spain, 2020

Primo 2020, Moderator, İstanbul, Turkey, 2020

Primo 2020, Invited Speaker, İstanbul, Turkey, 2020

WebTarged Tıp Araştırmaları Geliştirme ve Eğitim Derneği Web Portalı , Invited Speaker, İstanbul, Turkey, 2020

Van Multidisipliner Onkoloji Günleri , Moderator, Van, Turkey, 2020

COVID-19 Günlerinde Onkolojide Yenilikler E-Sempozyumu, Invited Speaker, İstanbul, Turkey, 2020

Onkoloji Okulum AACR'dan ASCO'ya Onkoloji Pratiğimizde Yansıyacıklar, Invited Speaker, İstanbul, Turkey, 2020

Hacettepe Onkoloji Günleri , Invited Speaker, Ankara, Turkey, 2020

COVID-19 Pandemisi Sürecinde Kanser Hastalarının Yönetimi, Invited Speaker, İstanbul, Turkey, 2020

Türk Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2020

UZMANIYLA, Invited Speaker, İstanbul, Turkey, 2020

Meme Tümörleri Kursu, Invited Speaker, İstanbul, Turkey, 2020

3. Gençlerle Onkolojiye Bakış Kongresi, Moderator, Antalya, Turkey, 2020

Memorial Şişli Onkoloji Toplantıları I – Meme Kanseri Yeni Yaklaşımlar, Invited Speaker, İstanbul, Turkey, 2020

Meme Kanseri Artırılmış Hedefe Yönelik Tedavi: Her Geçen Gün Daha İyiye Toplantısı, Invited Speaker, İstanbul, Turkey, 2020

Marmara Anadolu Yakası Meme Hastalıkları Sürekli Eğitim Toplantıları (MAYMET), Session Moderator, İstanbul, Turkey, 2020

Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2020

TÜRK TIBBİ ONKOLOJİ DERNEĞİ Strateji Arama Toplantısı 2020 - 2024 , Attendee, İstanbul, Turkey, 2020

6th Congress of the Mediterranean Multidisciplinary Oncology Forum & 3rd International Congress on Oncological Sciences, Invited Speaker, İstanbul, Turkey, 2019

1st Pan Albanian Conference on Breast Cancer, Invited Speaker, İstanbul, Turkey, 2019

Meme Kanseri: Çalışmalar Işığında Deneyim Paylaşımı Toplantısı, Invited Speaker, İstanbul, Turkey, 2019

3. İmmünoterapi ve Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2019

15. Ulusal Meme Hastalıkları Kongresi, Moderator, Antalya, Turkey, 2019

15. Ulusal Meme Hastalıkları Kongresi, Invited Speaker, Antalya, Turkey, 2019

6. Karadeniz Onkoloji Günleri, Panelists, Trabzon, Turkey, 2019

Practical Recommendations in Immuno & Molecular Oncology 2019, Invited Speaker, London, England, 2019

Practical Recommendations in Immuno & Molecular Oncology 2019, Invited Speaker, London, England, 2019

Yarınlara Açılan Pencere – Faslodex Toplantısı, Invited Speaker, İstanbul, Turkey, 2019

ROCHE Turkey Breast Cancer Expert Meeting, Invited Speaker, İstanbul, Turkey, 2019

23.Ulusal Kanser Kongresi, Invited Speaker, Antalya, Turkey, 2019

23. Ulusal Kanser Kongresi, Panelists, Antalya, Turkey, 2019

23. Ulusal Kanser Kongresi, Invited Speaker, Antalya, Turkey, 2019

Hedef Kanser 2019, Panelists, Antalya, Turkey, 2019

Kanser Rehabilitasyonuna Güncel Bakış Sempozyumu, Invited Speaker, İstanbul, Turkey, 2019

Roche Meme Kanseri Danışma Kurulu Toplantısı, Attendee, İstanbul, Turkey, 2019

12th Breast Cancer Academy Module 2019, Attendee, Barcelona, Spain, 2019

2. Gençlerle Onkolojiye Bakış Kongresi, Moderator, Antalya, Turkey, 2019

Abemaciclib Danışma Kurulu Toplantısı, Attendee, İstanbul, Turkey, 2019

III. Azerbaycan Medikal Onkoloji ve Nükleer Tıp Sempozyumu, Invited Speaker, Baku, Azerbaijan, 2019

Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2019

HER2+ Meme Kanseri Tedavisinde Dünden Bugüne Gelişmeler Toplantısı, Invited Speaker, İstanbul, Turkey, 2018

CEE Metastatic Breast Cancer Advisory Board – Munich, Invited Speaker, Munich, Germany, 2018

14. Ulusal Onkolojik Araştırmalar Çalıştayı, Working Group, İstanbul, Turkey, 2018

Pfizer Onkoloji Danışma Kurulu Toplantısı, Attendee, İstanbul, Turkey, 2018

3rd International İstanbul Breast Cancer Conference, Moderator, İstanbul, Turkey, 2018

3rd International İstanbul Breast Cancer Conference, Working Group, İstanbul, Turkey, 2018

3rd International İstanbul Breast Cancer Conference, Invited Speaker, İstanbul, Turkey, 2018

4. Marmara Üniversitesi Eczacılık Fakültesi Öğrenci Kongresi, Invited Speaker, İstanbul, Turkey, 2018

Best of ASCO 2018, Invited Speaker, İstanbul, Turkey, 2018

6. Uludağ Tıbbi Onkoloji Sempozyumu, Invited Speaker, Bursa, Turkey, 2018

Acıbadem Altunizade Onkoloji Okulu – Sağlık Söyleşisi, Invited Speaker, İstanbul, Turkey, 2018

7. Türk Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2018

7. Türk Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2018

Gençlerle Onkolojiye Bakış Kongresi, Panelists, Antalya, Turkey, 2018

Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2018

Ödüllü İnteraktif Meme Kanseri Kursu, Working Group, İstanbul, Turkey, 2017

Ödüllü İnteraktif Meme Kanseri Kursu, Working Group, İstanbul, Turkey, 2017

IMAG 26. Olgu Toplantısı, Invited Speaker, İstanbul, Turkey, 2017

A Montpellier University School of Medicine Diploma Program MONOSMED Course, Panelists, İstanbul, Turkey, 2017

A Montpellier University School of Medicine Diploma Program MONOSMED Course, Invited Speaker, İstanbul, Turkey, 2017

Meme Kanseri Moleküler Onkoloji Sempozyumu”, Invited Speaker, İstanbul, Turkey, 2017

35. Zeynep Kâmil Jinek-Patoloji Kongresi, Invited Speaker, İstanbul, Turkey, 2017

2. Multidisipliner Onkoloji Günleri, Moderator, İstanbul, Turkey, 2017

Meme Kanseri Bilgi Güncelleme Sempozyumu, Invited Speaker, İstanbul, Turkey, 2017

8th Regional Oncology Forum Warsaw, Poland, Panelists, Lublin, Poland, 2017

Ulusal İmmünoterapi ve Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2017

14. Ulusal Meme Hastalıkları Kongresi, Moderator, Antalya, Turkey, 2017

14. Ulusal Meme Hastalıkları Kongresi, Invited Speaker, Antalya, Turkey, 2017

Women Oncology Conference 2017 “Precision to Practice, Invited Speaker, İstanbul, Turkey, 2017

Meme Kanseri Çalışma Grubu, “13. Ulusal Onkolojik Araştırmalar Çalıştayı, Working Group, İstanbul, Turkey, 2017

4. Karadeniz Onkoloji Sempozyumu, Invited Speaker, Trabzon, Turkey, 2017

International Congress on Oncological Sciences, Invited Speaker, İstanbul, Turkey, 2017

22. Ulusal Kanser Kongresi, Moderator, Antalya, Turkey, 2017

22. Ulusal Kanser Kongresi, Invited Speaker, Antalya, Turkey, 2017

Cancer Bioimmunotherapy: An Evolving Field in the Treatment of Cancer Symposium, Moderator, Barcelona, Spain, 2017

Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2017

TÜBA – Klinik Araştırmalarda Faz Çalışmaları ve Etik Kurallar Çalıştayı, Invited Speaker, İstanbul, Turkey, 2017

1. Ulusal Vakalarla Onkoloji Kongresi, Invited Speaker, İstanbul, Turkey, 2017

Central and Eastern Europe 3rd Breast Cancer Working Group Meeting, Invited Speaker, İstanbul, Turkey, 2016

2nd International İstanbul Breast Cancer Conference, Invited Speaker, İstanbul, Turkey, 2016

HER2+ Metastatik Meme Kanseri Tedavisinde Güncel Yaklaşımlar ve Vaka Paylaşımları Toplantısı, Invited Speaker, İstanbul, Turkey, 2016

HER2+ Metastatik Meme Kanseri Tedavisinde Güncel Yaklaşımlar ve Vaka Paylaşımları Toplantısı, Invited Speaker, İstanbul, Turkey, 2016

12. Ulusal Onkolojik Araştırmalar Çalıştayı, Working Group, Antalya, Turkey, 2016

Acıbadem Üniversitesi Atakent Hastanesi Jinekolojik Tümörlerde Tartışmalı Konular Sempozyumu, Moderator, İstanbul, Turkey, 2016

3. İmmüno-Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, Invited Speaker, İstanbul, Turkey, 2016

20. Ulusal Cerrahi Kongresi, Panelists, Antalya, Turkey, 2016

20. Ulusal Cerrahi Kongresi, Invited Speaker, Antalya, Turkey, 2016

6. Türk Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2016

Araştırmalara Bakış ve İstatistik Kursu, Invited Speaker, İstanbul, Turkey, 2016

6. Türk Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2016

2. Ege Hematoloji Onkoloji Kongresi, Invited Speaker, İzmir, Turkey, 2016

Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2016

7. İstanbul Bilim Üniversitesi Onkoloji Günleri, Invited Speaker, İstanbul, Turkey, 2015

Meme Kanseri Güncel Tedavisinde Algoritmik Yaklaşım Toplantısı, Panelists, İstanbul, Turkey, 2015

11. Ulusal Onkolojik Araştırmalar Çalıştayı, Invited Speaker, Antalya, Turkey, 2015

13. Ulusal Meme Hastalıkları Kongresi, Invited Speaker, Antalya, Turkey, 2015

Acıbadem Üniversitesi Tıp Fakültesi ve SENATÜRK Senoloji Akademisi Ortak Eğitim Programı – Meme Kanseri Bireyselleştirilmiş Yaklaşımda Moleküler Onkoloji Sempozyumu, Invited Speaker, İstanbul, Turkey, 2015

2nd International Acıbadem Oncology Meeting, Invited Speaker, İstanbul, Turkey, 2015

1. Multidisipliner Onkoloji Günleri, Moderator, İstanbul, Turkey, 2015

12. Ulusal Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2015

New Horizons in Oncology: Breast Cancer – Anadolu Medical Center Oncological Sciences Symposium 3, Invited Speaker, İstanbul, Turkey, 2015

New Horizons in Oncology: Breast Cancer – Anadolu Medical Center Oncological Sciences Symposium 2, Invited Speaker, İstanbul, Turkey, 2015

Perjeta ve Kadcylla Danışma Kurulu Toplantısı, Attendee, İstanbul, Turkey, 2015

2. İmmüno – Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, Invited Speaker, Antalya, Turkey, 2015

21. Ulusal Kanser Kongresi, Invited Speaker, Antalya, Turkey, 2015

Hedef Kanser 2015 Toplantısı, Invited Speaker, Antalya, Turkey, 2015

IMAG 15. Olgu Toplantısı, Working Group, İstanbul, Turkey, 2015

4th AROME Radiobiology Course and Lnnovations: From Biology to Clinical Practice of Hypo Fractionation and Stereotactic Radiotherapy, Moderator, İstanbul, Turkey, 2015

Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2015

12. İstanbul Üniversitesi Onkoloji Enstitüsü Günleri Sempozyumu ve 5. Onkoloji Enstitüsü Çalıştayı, Invited Speaker, İstanbul, Turkey, 2014

Meme Kanseri Değere Dayalı Kaliteli Hizmetin Pratiğe Yansımaları Toplantısı, Invited Speaker, İstanbul, Turkey, 2014

I. Acıbadem Multidisipliner Kanser Sempozyumu, Invited Speaker, İstanbul, Turkey, 2014

14. Ulusal Jinekolojik Onkoloji Kongresi, Invited Speaker, İstanbul, Turkey, 2014

Palbociclib Danışma Kurulu Toplantısı, Attendee, İstanbul, Turkey, 2014

LİV Sempozyum Günleri, Working Group, İstanbul, Turkey, 2014

10. Onkolojik Araştırmalar Çalıştayı, Working Group, İstanbul, Turkey, 2014

Meme Kanseri Sonrası Yaşam Sağlık Söyleşisi – Acıbadem Kozyatağı Hastanesi, Invited Speaker, İstanbul, Turkey, 2014

11. Ulusal Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2014

Individualized Treatment for Breast Cancer Patients, Attendee, İstanbul, Turkey, 2014

Meme Kanseri Bireyselleştirilmiş Tedavi Sempozyumu, Working Group, İstanbul, Turkey, 2014

Farklı Yönleri ile Meme Kanseri Sempozyumu, Invited Speaker, İstanbul, Turkey, 2014

1st Hellenic – Turkish Congress on Senology New Aspects on Diagnosis and Treatment of Breast Diseases, Invited Speaker, İstanbul, Turkey, 2014

Breast Cancer in the Molecular Era: The Role of Gene Expression Based Assays, Moderator, İstanbul, Turkey, 2014

IMAG Olgu Toplantısı, Working Group, İstanbul, Turkey, 2014

Ankara Üniversitesi Onkoloji Uygulama ve Araştırma Merkezi Aylık Konferansları, Invited Speaker, Ankara, Turkey, 2014

2. Ege Hematoloji Onkoloji Sempozyumu, Invited Speaker, İzmir, Turkey, 2014

Meme Kanseri Bilgilendirme Paneli – Acıbadem Kozyatağı Hastanesi, Invited Speaker, İstanbul, Turkey, 2014

Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2014

IMAG Olgu Toplantısı, Working Group, İstanbul, Turkey, 2013

Tıbbi Onkoloji Derneği – Temel Teorik ve Pratik Klinik Araştırmalar Kursu, Invited Speaker, İstanbul, Turkey, 2013

Demanding Future of Breast Cancer Management – Kocaeli University, Invited Speaker, Kocaeli, Turkey, 2013

Herceptin'in 10 Yıllık Yolcuğu Toplantısı, Invited Speaker, İstanbul, Turkey, 2013

Marmara Anadolu Yakası Meme Hastalıkları Sürekli Eğitim Toplantıları (MAYMET), Invited Speaker, İstanbul, Turkey, 2013

9. Ulusal Onkolojik Araştırmalar Çalıştayı, Invited Speaker, İstanbul, Turkey, 2013

Türk Tıbbi Onkoloji Derneği, Attendee, Düzce, Turkey, 2013

Meme Kanseri Ustalık Kursu (MASTERCLASS), Invited Speaker, İstanbul, Turkey, 2013

12. Ulusal Meme Hastalıkları Kongresi, Invited Speaker, Antalya, Turkey, 2013

MED-INDEX Sürekli Tıp Eğitimi Etkinliği – Bireyselleşmiş Tedavide Odaklanmış Disiplinler Arası İşbirliği Toplantısı, Invited Speaker, İstanbul, Turkey, 2013

10. Ulusal Tıbbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2013

Meme Kanseri Karşı Yalnız Değilsiniz – Sağlık Söyleşisi, Invited Speaker, İstanbul, Turkey, 2013

1-7 Nisan Kanseri Haftasına Özel Sağlık Söyleşisi – Acıbadem Kozyatağı Hastanesi, Moderator, İstanbul, Turkey, 2013

Kansere Karşı Yalnız Değilsiniz Meme Kanseri Hastaları Destek Grubu Toplantıları – Acıbadem Kozyatağı Hastanesi, Invited Speaker, İstanbul, Turkey, 2013

ANADOLU TIBBİ ONKOLOJİ DERNEĞİ Meme Kanseri Tartışmalı Konular Sempozyumu, Invited Speaker, Afyonkarahisar, Turkey, 2013

Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Invited Speaker, İstanbul, Turkey, 2013

Kansere Karşı Yalnız Değilsiniz Meme Kanseri Hastaları Destek Grubu Toplantıları – Acıbadem Maslak Hastanesi, Invited Speaker, İstanbul, Turkey, 2013

Meme Kanseri Uzun Yaşamın Kalitesi Toplantısı, Invited Speaker, İstanbul, Turkey, 2012

8. Ulusal Onkolojik Araştırmalar Çalıştayı, Invited Speaker, Antalya, Turkey, 2012

ISC Conference on Innovative Therapies, Invited Speaker, İstanbul, Turkey, 2012

Oncotype DX Breast Cancer Forum Preliminary Agenda, Invited Speaker, İstanbul, Turkey, 2012

Marmara Anadolu Yakası Meme Hastalıkları Sürekli Eğitim Toplantıları (MAYMET), Invited Speaker, İstanbul, Turkey, 2012

Herceptin sc Danışma Kurulu Toplantısı, Attendee, İstanbul, Turkey, 2012

Best of ASCO 2012, Invited Speaker, İstanbul, Turkey, 2012

Abraxane Danışma Kurulu Toplantısı, Attendee, İstanbul, Turkey, 2012

Onkoloji Hastalarında Sindirim Sistemi Sorunlarına Yaklaşım Toplantısı, Invited Speaker, İstanbul, Turkey, 2012

Cerrahpaşa Cerrahi Toplantıları- Olgular Eşliğinde Meme Hastalıklarına Güncel Yaklaşım, Panelists, İstanbul, Turkey, 2012

Meme Kanseri Bilgilendirme Toplantısı, Invited Speaker, İstanbul, Turkey, 2012

Ulusal Kanseri Haftası Sempozyumu, Invited Speaker, İstanbul, Turkey, 2012

17. Ege Onkoloji Günleri, Invited Speaker, İzmir, Turkey, 2012

4. Tıbbi Onkoloji Kongresi, Invited Speaker, İstanbul, Turkey, 2012

Marmara Anadolu Yakası Meme Hastalıkları Sürekli Eğitim Toplantıları – MAYMET) , Invited Speaker, İstanbul, Turkey, 2011

Department of Medicine And Gastroenterology Symposium, Invited Speaker, İstanbul, Turkey, 2011

2nd Congress of the Mediterranean Multidisciplinary Oncology Forum, Invited Speaker, İstanbul, Turkey, 2011

7. Ulusal Onkolojik Araştırmalar Çalıştayı, Working Group, Antalya, Turkey, 2011

Onkolojide Oral Sistemik Tedaviler Toplantısı, Invited Speaker, İstanbul, Turkey, 2011

6. Ulusal Onkolojik Araştırmalar Çalıştayı, Invited Speaker, Antalya, Turkey, 2010

Invited Talks

American Society of Clinical Oncology, Conference, ASCO, United States Of America, June 2024

Meme Kanseri Tedavisinde Güncel Yaklaşımlar, Conference, Azerbeycan Milli Onkoloji Merkezi, Turkey, March 2024

Management of HR+ Her-2 neg metastatic breast cancer, Seminar, Bahrain- Novartis breast cancer seminar, Bahrain, February 2024

II. International Baku Breast Cancer Congress, Conference, Azerbaijan, October 2023

Neoadjuvant systemic therapy in early breast cancer, Conference, Senologic International Society World congress on Breast Cancer, Greece, May 2023

Awards

Başaran G., Işıklar A., Soyder A., Yazıcı H., Ekmekçi C., 26 genlik ailesel meme kanseri paneli ile taranan genç (40 yaş) meme kanseri hastalarının özellikleri ve sağkalımı, Türk Tıbbi Onkoloji Derneği, November 2021

Başaran G., Basaran G, Cabuk D, Korkmaz T, Kocar M, Telli F, Dane F, Yumuk F, Turhal S. Clinical, pathological factors predicting early relapse in hormone receptor early breast cancer. Best Abstracts Presented at BUON Congress 2010, 2. Buon Congress 2010, September 2010

Başaran G., Ozturk MA, Dane F, Karagoz S, Tural D, Demirelli F, Basaran G, Buyukunal E, Mandel NM, Erdamar S, Turna H, Seber S, Turhal S, Serdengeci S. The prognostic value of perineural invasion in patients with early stage colon cancer., Best Abstracts Presented at BUON Congress 2010, 3. Buon Congress 2010, September 2010

Başaran G., 4. Basaran G, Okkan S, Caglar H, Benekli M, Haydaroğlu A, Eralp Y, Abalı H, Yıldız F, Beşe N, Gursel B, Guney N, Derin D HER-2 Eekpresyonu ve hormon reseptörleri bilinen T1N0 Meme Kanserli Hastaların Retrospektif Analizi. En iyi TOG çalışması, 5. Ulusal Onkolojik Araştırmalar Çalıştayı, November 2009

Başaran G., 6. Dane F, Gümüş M, Yaman E, Öztürk MA, Sevinç A, Atasoy BM, Çabuk D, İyikesici S, Yumuk PF, Başaran GA, Abacıoğlu U, Teomete M, Turhal NS. Küratif olarak rezeke edilmiş evre II-III rektum kanserli Türk hasta popülasyonunun adjuvan kemoradyoterapi sonuçları, prognostik özellikleri ve sağkalım analizleri, çok merkezli retrospektif çalışma 6. En İyi Bildiri Ödülü, 6. Marmara Üniversitesi Tıp Fakültesi 4. Araştırma Günleri , October 2009

Başaran G., 5. Dane F, Gümüş M, Öztürk MA, Atasoy BM, İyikesici S, Yumuk PF, Başaran G, Abacıoğlu U, Çabuk DÖ, Teomete M, Turhal NS, "Rektum Kanseri Olgularının Klinik Özellikleri ve Adjuvan Kemoradyoterapi Sonuçları: Tek Merkez Tecrübesi, 5. Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, March 2008

Başaran G., 3. Uluslararası Yayın Teşvik ve Destek ödülü, 3. Marmara Üniversitesi, November 2002

Başaran G., 2. Best poster award. Breast International Group (BIG) survey of medical oncologists attitudes to the management of elderly patients (pts) with early breast cancer. Biganzoli L, Goldhirsch A, Straehle C, Castiglione M, Therasee P, Vogt G, Apro M, Atalay G, Piccart M. Ann Oncol 2002 13 (suppl 5)9105(abstract 380P) Received best poster award., 2. Esmo 2002, September 2002

Başaran G., Best poster/presentation award. Outcome of patients after adjuvant treatment for breast cancer. Atalay G, Turhal NS. 11th International Congress on Anti-Cancer Treatment, 1. Somsps 2001, February 2001

Representation and Promotion Activities

Institutional Representation, Switzerland, Basel, 2021 - 2026

Institutional Representation, Mehmet Ali Aydınlar Üniversitesi Tıp Fakültesi, Turkey, İstanbul, 2022 - 2022